Status:

COMPLETED

Rosiglitazone And Plaque Study for Type 2 Diabetes Mellitus

Lead Sponsor:

GlaxoSmithKline

Conditions:

Non-insulin-dependent Diabetes Mellitus

Eligibility:

All Genders

30-75 years

Phase:

PHASE3

Brief Summary

This is a phase IIIb, randomised, double blind, placebo controlled, study in patients with type 2 diabetes mellitus and coexisting vascular disease or hypertension. The total duration of the study wil...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Type 2 diabetes.
  • Co-existing vascular disease.
  • At least 6 months of statin or fibrate therapy.
  • HbA1c \<10% at screening and with at least one atheromatous plaque causing 10-95% narrowing of the internal carotid artery.
  • Exclusion criteria:
  • Patients with \>2 concomitant oral anti-hyperglycaemic agents within 3 months of screening.
  • Previous exposure to a thiazolidinedione.
  • History of chronic insulin use.
  • Use of investigational drug within 30 days.
  • Systolic blood pressure (bp) \> 170 mmHg or diastolic bp \>100 mmHg.
  • Severe or unstable angina.
  • History of: gangrene, TIA, stroke, hepatic disease, alcohol or drug abuse, surgery of the carotid arteries or claustrophobia.

Exclusion

    Key Trial Info

    Start Date :

    September 1 2002

    Trial Type :

    INTERVENTIONAL

    End Date :

    May 1 2005

    Estimated Enrollment :

    60 Patients enrolled

    Trial Details

    Trial ID

    NCT00231387

    Start Date

    September 1 2002

    End Date

    May 1 2005

    Last Update

    January 23 2017

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    GSK Clinical Trials Call Center

    London, United Kingdom, W2 1NY